These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 3815359)

  • 1. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
    Kramer RA; Greene K; Ahmad S; Vistica DT
    Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
    Ono K; Shrieve DC
    J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
    Smith AC; Liao JT; Page JG; Wientjes MG; Grieshaber CK
    Cancer Res; 1989 Oct; 49(19):5385-91. PubMed ID: 2766304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U; Cao S; Minderman H; Toth K; Skenderis BS; Slovak ML; Rustum YM
    Clin Cancer Res; 1996 Dec; 2(12):1961-8. PubMed ID: 9816155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
    Anderson CP; Reynolds CP
    Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
    Soble MJ; Dorr RT
    Anticancer Res; 1988; 8(1):17-22. PubMed ID: 3358633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of L-phenylalanine mustard and L-buthionine sulfoximine on murine and human hematopoietic progenitor cells in vitro.
    Du DL; Volpe DA; Grieshaber CK; Murphy MJ
    Cancer Res; 1990 Jul; 50(13):4038-43. PubMed ID: 2354454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE; Hahn SM; Cook JA; Lipschultz C; Mitchell JB; Kaufman DC
    Cancer Res; 1993 May; 53(9):2066-70. PubMed ID: 8097674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links.
    Chen G; Zeller WJ
    Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines.
    Peters RH; Jollow DJ; Stuart RK
    Cancer Res; 1991 May; 51(10):2536-41. PubMed ID: 2021933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery.
    Bertsche U; Schorn H
    Radiat Res; 1986 Mar; 105(3):351-69. PubMed ID: 3754339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
    Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
    Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
    Skapek SX; Colvin OM; Griffith OW; Elion GB; Bigner DD; Friedman HS
    Cancer Res; 1988 May; 48(10):2764-7. PubMed ID: 3359437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells.
    Dusre L; Mimnaugh EG; Myers CE; Sinha BK
    Cancer Res; 1989 Feb; 49(3):511-5. PubMed ID: 2535960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intercellular transfer of drug resistance.
    Frankfurt OS; Seckinger D; Sugarbaker EV
    Cancer Res; 1991 Feb; 51(4):1190-5. PubMed ID: 1997161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
    Xu BH; Singh SV
    Cancer Res; 1992 Dec; 52(23):6666-70. PubMed ID: 1423311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective enhancement of hypoxic cell killing by melphalan via thiol depletion: in vitro studies with hypoxic cell sensitizers and buthionine sulfoximine.
    Roizin-Towle L
    J Natl Cancer Inst; 1985 Jan; 74(1):151-7. PubMed ID: 3155814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells.
    Dethlefsen LA; Lehman CM; Biaglow JE; Peck VM
    Radiat Res; 1988 May; 114(2):215-24. PubMed ID: 3375425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
    O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
    J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of glutathione depletion by buthionine sulfoximine on radiosensitization by oxygen and misonidazole in vitro.
    Shrieve DC; Denekamp J; Minchinton AI
    Radiat Res; 1985 Jun; 102(3):283-94. PubMed ID: 4070545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.